Evidence map›Paper›PMID 39691063›Full record

ArticleFuture medicinal chemistry2025

Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer.

Caleb M T Kam, Amanda L Tauber, Matthew S Zunk, Catherine M McDermott, Stephan M Levonis, Stephanie S Schweiker

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Caleb M T KamMedicinal Chemistry Group, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia.
Amanda L TauberMedicinal Chemistry Group, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia.
Matthew S ZunkSchool of Pharmacy and Medical Sciences, Griffith University, Southport, Queensland, Australia.
Catherine M McDermottCentre for Urology Research, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia.
Stephan M LevonisMedicinal Chemistry Group, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia.
Stephanie S SchweikerMedicinal Chemistry Group, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPoly(ADP-ribose) polymerase (PARP) is a superfamily of enzymes involved in cell survival. Both PARP1 and PARP14 are overexpressed in malignancies. No clinically approved PARP14 inhibitors are available, and PARP1 inhibitors are generally nonspecific, resulting in a need for a more diverse library of selective PARP1 and PARP14 inhibitors. MATERIALS AND

methodsBased on the previous lead compounds RESULTS AND

conclusionThe 26 novel compounds demonstrated a lesser inhibitory effect than the lead compounds. Compounds

Indexed as

Antineoplastic AgentsCell SurvivalCisplatinDrug DesignPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorDrug SynergismHumansMolecular Docking SimulationMolecular StructureNeoplasmsStructure-Activity RelationshipAntineoplastic AgentsCisplatinPARP14 protein, humanPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) Polymerasescell culturecell viability assaysMedicinal chemistryorganic synthesisPARP assaysPARP inhibitors

Identifiers

PMID39691063
PMCPMC11703142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.